3Bellomo R, Tipping P, Boyce N. Continuous venovenous hemofiltration with dialysis removes cytokines from the circulation of septic patients. CritCare Med, 1993, 21:522
5Heering R, Morgera S, Schmitz G et al. Cytokines removal and cardiovascular hemodynamics in septic patients with continuous hemofiltration.Intensive Care Med, 1997, 23:288
6Kada Kouche, Pierre Cavadore, Pierre Portales et al. Continuous venovenous hemofiltration improves hemodynamics in septic shock with acute renal failure without modifying TNF-α and IL-6 plasma concentrations. J Nephrol, 2002, 15:150
7Sander A, Armbruster W, Sander B et al. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF-α plasma concentrations. Intensive Care Med, 1997,23: 878
8Richard S, Hotchkiss M.D, Irene E et al. The pathophysiology and treatment of sepsis. New Engl J Med, 2003, 348:138
9Bulthazar EJ, Ranson JHC, Naidich DP et al. Acute pancreatitis: prognostic value of CT. Radiology, 1985, 156
10Sibbald WJ, Vincent JL. Round table conference on clinical trial for the treatment of sepsis. Crit Care Med, 1995, 23:394
2Ikezoe T, Yang Y, Heber D, et al. PC-SPES: a potent inhibitor of nuclear factor-kappa B rescues mice from lipopolysaccharide-induced septic shock [J]. Mol Pharmacol, 2003, 64(6) : 1521
3O'Reilly M, Neweomb DE, Remick D. Endotoxin, sepsis, and the primrose path [J]. Shock, 1999; 12(6) :411
4Flammand FJ, Sibbald WJ, Girotti MJ, et al. Pentoxifylline does not prevent microvascular injury in normotensive, septic rats[J]. Crit Care Med, 19951 23(1):119
5Kumagai T, Kawamoto Y, Nakamura Y, et al. 4-hydroxy-2- nonenal, the end product of lipid peroxidation, is a specific inducer of eyelooxygenase-2 gene expression[J]. Bioehem Biophys Res Commun, 2000; 273(2) :437
6Keller SA, Paxian M, Lee SM, et al. Kupffer cell ablation attenuates cyclooxygenase-2 expression after trauma and sepsis [J]. J Surg Res, 2005; 124(1):126
7Frost RA, Nystrom GJ, Lang CH. Lipopolysaccharide regulates proinflammatory cytokine expression in mouse myoblasts and skeletal muscle [J]. Am J Physiol Regul Integr Comp Physiol, 2002, 283(3):R698
8Remick DG, Call DR, Ebong SJ, et al. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality [J]. Crit Care Med, 2001; 29(3) : 473
9Berg DJ, Zhang J, Lauricella DM, etal. IL-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production [J]. J Immunol, 2001, 166(4) :2674
10Strong VE, Mackrell PJ, Concannon EM, et al. Blocking prostaglandin E2 after trauma attenuates pro-inflammatory cytokines and improves survival [J]. Shock, 2000, 14(3) : 374
